Barclays analyst Etzer Darout raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $225 from $224 and keeps an Overweight rating on the shares. The firm adjusted ratings and targets in the small and mid cap biotechnology group as part of a Q1 earnings preview.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Nike downgraded, IBM initiated: Wall Street’s top analyst calls
- Jazz Pharmaceuticals resumed with an Outperform at Raymond James
- Jazz Pharmaceuticals price target raised to $232 from $219 at Piper Sandler
- Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026
- Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting